- Home
- TPST vs LGVN Comparison
TPST vs LGVN Comparison
Compare TPST & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | LGVN |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 34.0M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TPST | LGVN |
|---|---|---|
| Price | $2.36 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $11.00 | $3.00 |
| AVG Volume (30 Days) | 267.3K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | $295,000.00 | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.48 |
| 52 Week High | $12.22 | $1.83 |
Technical Indicators
Market Signals| Indicator | TPST | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 57.97 |
| Support Level | $2.14 | $0.69 |
| Resistance Level | $2.49 | $1.23 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 88.54 | 60.45 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.